Amerikanische Gesellschaft für Hirudotherapie

NMR-based structural characterization of a two-disulfide-bonded analogue of the FXIIIa inhibitor tridegin

Structural biology published in International Journal of Molecular Sciences (2021)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungSpeichel-PharmakologieSchmitz T et al. · International journal of molecular sciences, 2021

Abstract

The saliva of blood-sucking leeches contains a plethora of anticoagulant substances. One of these compounds derived from Haementeria ghilianii, the 66mer three-disulfide-bonded peptide tridegin, specifically inhibits the blood coagulation factor FXIIIa. Tridegin represents a potential tool for antithrombotic and thrombolytic therapy. We recently synthesized two-disulfide-bonded tridegin variants, which retained their inhibitory potential. For further lead optimization, however, structure information is required. We thus analyzed the structure of a two-disulfide-bonded tridegin isomer by solution 2D NMR spectroscopy in a combinatory approach with subsequent MD simulations. The isomer was studied using two fragments, i.e., the disulfide-bonded N-terminal (Lys1-Cys37) and the flexible C-terminal part (Arg38-Glu66), which allowed for a simplified, label-free NMR-structure elucidation of the 66mer peptide. The structural information was subsequently used in molecular modeling and docking studies to provide insights into the structure-activity relationships. The present study will prospectively support the development of anticoagulant-therapy-relevant compounds targeting FXIIIa.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsDisulfidesFactor XIIIaFibrinolytic AgentsHumansIsomerismLeechesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyModels, MolecularMolecular Dynamics Simulation

Zusammenfassung

NMR structural characterization of two-disulfide tridegin variants reveals key folds for FXIIIa inhibition — insights for next-generation leech-derived inhibitor design.

Warum dies für die Hirudotherapie relevant ist

This study reports the solution NMR structure of a two-disulfide-bonded analogue of tridegin, a 66-mer peptide from the leech Haementeria ghilianii that specifically inhibits blood coagulation factor FXIIIa, using a two-fragment approach combined with molecular dynamics simulations. The work matters for hirudotherapy and the leech secretome because it advances lead optimization of a leech-derived antithrombotic/thrombolytic candidate toward potential therapeutic development targeting FXIIIa. The structural data support molecular modeling and docking studies aimed at understanding structure-activity relationships. The honest caveat is that this is a preclinical biophysical study; it involves no animal or human subjects, no leech therapy, and the therapeutic relevance is prospective—the abstract does not claim clinical efficacy or FDA approval.

Zitation

NMR-based structural characterization of a two-disulfide-bonded analogue of the FXIIIa inhibitor tridegin.

Schmitz T et al. · International journal of molecular sciences, 2021

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.